SOBEL ALAN D. purchased 28.4% of their position (22.56K shares) of CYTOSORBENTS CORP on the open market
Open‑market purchase worth $30.0K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 12/15/2023ACC: 0001104659-23-126432
+30.45K
Net shares
Net buyer
$30.0K
Total acquired
1
Open market trades
1B · 0S
2
Total transactions
30.45K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+22.56K
Price / share
$1.33
Trade value
$30K
% of position
28.4%
12/13/2023
79.30K→101.86K
Total
Net shares
+22.56K
Net value
$30K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/13/2023 | P · Purchase | +22.56K | $1.33 | $30K | 28.4% | 79.30K | 101.86K |
| Total | +22.56K | $30K | ||||||
Derivative Transactions1
Common Stock Warrant (Right to Buy)
Direct
Converts to
Common Stock
7.89K shares
Shares
+7.89K
Strike price
2.00
Held after
7.89K
Exercisable
—
12/13/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Common Stock Warrant (Right to Buy) Direct | Common Stock7.89K shares | 12/13/2023 | P · Purchase | +7.89K | 2.00 | — | 7.89K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned2K
Total
2K indirect2K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 2K | Indirect |
| Total | 2K | 2K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported